Indication

Ataxia-telangiectasia

Ataxia-telangiectasia is a rare, autosomal recessive multisystem disorder caused by pathogenic variants in the *ATM* gene, which disrupt cellular responses to DNA double-strand breaks and lead to genomic instability. Read more about Ataxia-telangiectasia

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Ataxia-telangiectasia therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Ataxia-telangiectasia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Ataxia-telangiectasia.

Ataxia-telangiectasia is a rare, autosomal recessive multisystem disorder caused by pathogenic variants in the *ATM* gene, which disrupt cellular responses to DNA double-strand breaks and lead to genomic instability.

Typically presenting in early childhood, it primary affects the central nervous and immune systems, as well as the vasculature.

Hallmark clinical features include progressive cerebellar ataxia, oculomotor apraxia, choreoathetosis, and oculocutaneous telangiectasias, which are prominent dilated blood vessels on the conjunctiva and skin.

Affected individuals also demonstrate significant cellular and humoral immunodeficiency with recurrent sinopulmonary infections, profound hypersensitivity to ionizing radiation, and a markedly elevated predisposition to malignancies, particularly leukemias and lymphomas.

Personalize your experience

Follow Ataxia-telangiectasia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it